ASCO Breast Cancer Biomarkers GUIDELINES App
Issue link: https://eguideline.guidelinecentral.com/i/848809
Î (Update of 2016 recommendation 1.8) If a patient has HER2-positive breast cancer, the clinician should NOT use the MammaPrint assay to guide decisions regarding adjuvant systemic therapy. (Moderate Recommendation; IC-L) • Additional studies are required to address the role of MammaPrint in patients with this tumor subtype who are also receiving HER2-targeted therapy. Î (Update of 2016 recommendation 1.9) If a patient has ER/PgR negative and HER2-negative breast cancer (triple negative), the clinician should NOT use the MammaPrint assay to guide decisions about adjuvant systemic chemotherapy. (Strong Recommendation; IC-Ins) PAM50 Risk of Recurrence Score Î If a patient has ER/PgR-positive, HER2-negative (node-negative) breast cancer, the clinician may use the PAM50 risk of recurrence (ROR) score (Prosigna Breast Cancer Prognostic Gene Signature Assay; NanoString Technologies, Seattle, WA), in conjunction with other clinicopathologic variables, to guide decisions on adjuvant systemic therapy. (Strong Recommendation; EB-H) Î If a patient has ER/PgR-positive, HER2-negative (node-positive) breast cancer, the clinician should NOT use the PAM50-ROR to guide decisions on adjuvant systemic therapy. (Moderate Recommendation; EB-I) Î If a patient has HER2-positive breast cancer, the clinician should NOT use the PAM50-ROR to guide decisions on adjuvant systemic therapy. (Strong Recommendation; IC-Ins) Î If a patient has TN breast cancer, the clinician should NOT use the PAM50-ROR to guide decisions on adjuvant systemic therapy. (Strong Recommendation; IC-Ins) Breast Cancer Index Î If a patient has ER/PgR-positive, HER2-negative (node-negative) breast cancer, the clinician may use the Breast Cancer Index to guide decisions on adjuvant systemic therapy. (Moderate Recommendation; EB-I) Î If a patient has ER/PgR-positive, HER2-negative (node-positive) breast cancer, the clinician should NOT use the Breast Cancer Index to guide decisions on adjuvant systemic therapy. (Strong Recommendation; IC-Ins) Î If a patient has HER2-positive breast cancer or TN breast cancer, the clinician should NOT use the Breast Cancer Index to guide decisions on adjuvant systemic therapy. (Strong Recommendation;IC-Ins) Diagnosis